The global heparin market size is
expected to reach USD 7.4 billion by 2026. It is projected to register a CAGR
of 1.6% during the forecast period. Rising prevalence cardiovascular disorders,
deep vein thrombosis, and renal diseases among other chronic diseases is
expected to boost the growth.
Access
Sample Report of this report @ https://www.radiantinsights.com/research/heparin-market/request-sample
According to the data published in the
American Heart Association, in 2018, approximately 92.1 million American adults
were living with some form of cardiovascular diseases. Coronary heart disease
is one of the leading cause of deaths in U.S. Furthermore, it was estimated
that more than 23.6 million deaths will be observed by 2030 due to
cardiovascular diseases.
Increasing demand for transfusion of
blood, blood components, and plasma derivatives during surgical procedures,
treatment of infectious diseases, and increasing survival rate are high impact
rendering drivers for growth of the heparin market during the forecast period.
Increasing demand for RBCs and platelets by various hospital divisions and
clinics is expected to have a positive impact on the growth.
Growing geriatric population is
anticipated to propel the market growth. According to an article published in
2018 in the United States Census Bureau, it is estimated that by 2035,
population aged 65 years and above is expected to reach 78 million whereas
children under the age of 18 may reach around 76.7million.
Rising incidence of immunological
diseases, thrombosis, and hemostasis is likely to result in high demand for
therapeutic plasma proteins. Manufacturing of plasma proteins led to an
increase in the demand for purified plasma, further expected to fuel the market
over the forecast period.
Further
key findings from the report suggest:
• Low molecular weight heparin led the
type segment in 2018 owing to its more predictable anticoagulant effect
• In 2018, ultra-low molecular weight
heparin was estimated to be the fastest growing segment, owing to
commercialization of enhanced version of products with improved pharmacological
effects
• Subcutaneous route of administration
led the market in 2018 and is estimated to be the fastest growing segment over
the forecast period due to ease of administration
• Coronary artery disease was considered
to be the largest application segment in 2018 and venous thromboembolism is
projected to be the fastest growing segment in near future
• In 2018, outpatient led the end use
segment and was estimated to register the fastest growth in the forthcoming
years
• North America held the largest market
share in 2018 owing to increasing prevalence of cardiovascular disorders and
sports injuries. Asia Pacific is estimated to be the fastest growing segment
over the forecast period
• Some of the key companies operating in
the heparin market are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma
A/S; Sanofi; Dr. Reddy's Laboratories Ltd.; Aspen Holdings; B. Braun Medical
Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd
About
Radiant Insights
Radiant Insights is a platform for
companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
Media
Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
No comments:
Post a Comment